Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...
Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...
Merck & Co’s Keytruda (pembrolizumab)—in combination with paclitaxel, with or without bevacizumab—has been approved in the ...
U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...
In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...
Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
In final draft guidance (PDF), NICE has said that Keytruda (pembrolizumab) can be used within NHS England as a treatment for ...
Zacks Investment Research on MSN
Can MRK's ongoing M&A push aid long-term growth ahead of Keytruda LOE?
Merck MRK has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, ...
After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The positive ...
9d
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results